Primary myelofibrosis (PMF) is a pluripotent hematopoietic stem cell-derived malignancy, included in the heterogeneous group of myeloproliferative neoplasms (MPNs). PMF diagnosis is based on a composite assessment of clinical and laboratory data. The three major diagnostic criteria are: screening for driver mutations, exclusion of other conditions that can cause myelofibrosis, and bone marrow biopsy displaying megakaryocyte changes and fibrosis. PMF treatment options are only partially disease-modifying and consist mainly of symptom control. Recently, a new targeted therapy was introduced for PMF patients, JAK-STAT inhibitors (i.e. ruxolitinib). However, specific subgroups of patients do not benefit from the JAK-STAT inhibitors: (1) those who are carrying JAK2 mutations, but ruxolitinib does not reduce the spleen size; (2) triple negative patients (no JAK2, CALR, or MPL mutations); and (3) those who discontinue JAK-STAT therapy because of side effects. These subgroups are in need of new therapeutic approaches. Mature microRNAs (miRNAs) range from 16 to 28 nucleotides (nt) in length and regulate specific messenger RNAs at the post-transcriptional level. Numerous in vitro and in vivo studies have reported specific miRNAs, as well as complex miRNA networks, to be dysregulated in PMF. Several of these miRNAs were shown to be implicated in essential events of PMF pathophysiology: increase of bone marrow fibrosis, progression to acute myeloid leukemia, resistance to JAK-STAT inhibitors, and activation of differentiation of hematopoietic stem/progenitor cells into megakaryocytes. Hence, we propose miRNAs as a potential minimally invasive diagnostic tool for PMF and as therapeutic targets that could address the unmet medical needs of these patients.

Keywords:

References

1. D. A. Arber, A. Orazi, R. Hasserjian, J. Thiele, M. J. Borowitz, M. M. Le Beau, C. D. Bloomfield, M. Cazzola and J. W. Vardiman, The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia, Blood 127 (2016) 2391–405. Crossref, Google Scholar
2. R. A. Mesa, S. Verstovsek, F. Cervantes et al., Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): Consensus on terminology by the international working group for myelofibrosis research and treatment (IWG-MRT), Leuk. Res. 31 (2007) 737–40. Crossref, Google Scholar
3. P. Guglielmelli, A. Pacilli, G. Rotunno et al., Presentation and outcome of patients with 2016 WHO diagnosis of prefibrotic and overt primary myelofibrosis, Blood 129 (2017) 3227–3236. Crossref, Google Scholar
4. X. Lu, R. Levine, W. Tong et al., Expression of a homodimeric type I cytokine receptor is required for JAK2V617F-mediated transformation, Proc. Natl. Acad. Sci. USA 102 (2005) 18962–7. Crossref, Google Scholar
5. D. Mclornan, M. Percy and M. F. Mcmullin, JAK2 V617F: A single mutation in the myeloproliferative group of disorders, Ulster Med. J. 75 (2006) 112–9. Google Scholar
6. Y. Pikman, B. H. Lee, T. Mercher et al., MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia, PLOS Med. 3 (2006) e270. Crossref, Google Scholar
7. T. Klampfl, H. Gisslinger, A. S. Harutyunyan et al., Somatic mutations of calreticulin in myeloproliferative neoplasms, N. Engl. J. Med. 369 (2013) 2379–90. Crossref, Google Scholar
8. P. Bose and S. Verstovsek, Prognosis of Primary Myelofibrosis in the Genomic Era, Clin. Lymphoma Myeloma. Leuk. 16 Suppl (2016) S105–13. Crossref, Google Scholar
9. A. Tefferi, P. Guglielmelli, A. Pardanani et al., Myelofibrosis treatment algorithm 2018, Blood Cancer J. 8 (2018) 72. Crossref, Google Scholar
10. K. K. Ballen, S. Shrestha, K. A. Sobocinski et al., Outcome of transplantation for myelofibrosis, Biol Blood Marrow Transplant 16 (2010) 358–67. Crossref, Google Scholar
11. M. Schieber, J. D. Crispino, B. Stein, Myelofibrosis in 2019: Moving beyond JAK2 inhibition, Blood Cancer J. 9 (2019) 74. Crossref, Google Scholar
12. S. Verstovsek, R. A. Mesa, J. Gotlib et al., A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis, N. Engl. J. Med. 366 (2012) 799–807. Crossref, Google Scholar
13. F. Cervantes, A. M. Vannucchi, J. J. Kiladjian et al., Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis, Blood 122 (2013) 4047–53. Crossref, Google Scholar
14. C. Harrison, J. J. Kiladjian, H. K. Al-Ali et al., JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis, N. Engl. J. Med. 366 (2012) 787–98. Crossref, Google Scholar
15. A. Tefferi, R. Vaidya, D. Caramazza et al., Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: A comprehensive cytokine profiling study, J. Clin. Oncol. 29 (2011b) 1356–63. Crossref, Google Scholar
16. H. M. M. Kvasnicka, M. D. Jürgen Thiele, E. Carlos, M. D. Bueso-Ramos et al., Effects of five-years of ruxolitinib therapy on bone marrow morphology in patients with myelofibrosis and comparison with best available therapy, Blood 122 (2013). Google Scholar
17. A. Tefferi, M. R. Litzow, A. Pardanani, Long-term outcome of treatment with ruxolitinib in myelofibrosis, N. Engl. J. Med. 365 (2011a) 1455–57. Crossref, Google Scholar
18. A. Pardanani, C. Harrison, J. E. Cortes et al., Safety and efficacy of fedratinib in patients with primary or secondary myelofibrosis: A randomized clinical trial, JAMA Oncol. 1 (2015) 643–51. Crossref, Google Scholar
19. J. Mascarenhas, R. Hoffman, M. Talpaz et al., Pacritinib vs best available therapy, including ruxolitinib, in patients with myelofibrosis: A randomized clinical trial, JAMA Oncol. 4 (2018) 652–659. Crossref, Google Scholar
20. M. Lu, L. Xia, Y. Li, X. Wang and R. Hoffman, The orally bioavailable MDM2 antagonist RG7112 and pegylated interferon alpha 2a target JAK2V617F-positive progenitor and stem cells, Blood 124 (2014) 771–9. Crossref, Google Scholar
21. B. Drexler, J. R. Passweg, A. Tzankov et al., The sympathomimetic agonist mirabegron did not lower JAK2-V617F allele burden, but restored nestin-positive cells and reduced reticulin fibrosis in patients with myeloproliferative neoplasms: Results of phase II study SAKK 33/14, Haematologica 104 (2019) 710–716. Crossref, Google Scholar
22. K. J. Newberry, K. Patel, L. Masarova et al., Clonal evolution and outcomes in myelofibrosis after ruxolitinib discontinuation, Blood 130 (2017) 1125–1131. Crossref, Google Scholar
23. A. Tefferi, P. Guglielmelli, D. R. Larson et al., Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis, Blood 124 (2014a) 2507–13; quiz 2615. Crossref, Google Scholar
24. S. Verstovsek, R. A. Mesa, J. Gotlib et al., Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial, J. Hematol. Oncol. 10 (2017) 55. Crossref, Google Scholar
25. R. C. Lee, R. L. Feinbaum and V. Ambros, The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14, Cell 75 (1993) 843–54. Crossref, Google Scholar
26. B. Wightman, I. Ha and G. Ruvkun, Posttranscriptional regulation of the heterochronic gene lin-14 by lin-4 mediates temporal pattern formation in C. elegans, Cell 75 (1993) 855–62. Crossref, Google Scholar
27. S. Griffiths-Jones, The microRNA registry, Nucleic Acids Res. 32 (2004) D109–11. Crossref, Google Scholar
28. S. Griffiths-Jones, R. J. Grocock, S. Van Dongen, A. Bateman and A. J. Enright, miRBase: MicroRNA sequences, targets and gene nomenclature, Nucleic Acids Res. 34 (2006) D140–4. Crossref, Google Scholar
29. S. Griffiths-Jones, H. K. Saini, S. Van Dongen and A. J. Enright, miRBase: Tools for microRNA genomics, Nucleic Acids Res. 36 (2008) D154–8. Crossref, Google Scholar
30. A. Kozomara, M. Birgaoanu and S. Griffiths-Jones, miRBase: From microRNA sequences to function, Nucleic Acids Res. 47 (2019) D155–D162. Crossref, Google Scholar
31. A. Kozomara and S. Griffiths-Jones, miRBase: Integrating microRNA annotation and deep-sequencing data, Nucleic Acids Res. 39 (2011) D152–7. Crossref, Google Scholar
32. A. Kozomara and S. Griffiths-Jones, miRBase: Annotating high confidence microRNAs using deep sequencing data, Nucleic Acids Res. 42 (2014) D68–73. Crossref, Google Scholar
33. A. Creugny, A. Fender and S. Pfeffer, Regulation of primary microRNA processing, FEBS Lett. 592 (2018) 1980–1996. Crossref, Google Scholar
34. T. Treiber, N. Treiber, G. Meister, Regulation of microRNA biogenesis and its crosstalk with other cellular pathways, Nat. Rev. Mol. Cell Biol. 20 (2019) 5–20. Crossref, Google Scholar
35. B. Fromm, D. Domanska, E. Hoye et al., MirGeneDB 2.0: the metazoan microRNA complement, Nucleic Acids Res. 48 (2020) D1172. Crossref, Google Scholar
36. Y. Lee, C. Ahn, J. Han et al., The nuclear RNase III Drosha initiates microRNA processing, Nature 425 (2003) 415–9. Crossref, Google Scholar
37. J. Han, Y. Lee, K. H. Yeom, Y. K. Kim et al., The Drosha-DGCR8 complex in primary microRNA processing, Genes Dev 18 (2004) 3016–27. Crossref, Google Scholar
38. M. T. Bohnsack, K. Czaplinski and D. Gorlich, Exportin 5 is a RanGTP-dependent dsRNA-binding protein that mediates nuclear export of pre-miRNAs, RNA 10 (2004) 185–91. Crossref, Google Scholar
39. G. Hutvagner, J. Mclachlan, A. E. Pasquinelli et al., A cellular function for the RNA-interference enzyme Dicer in the maturation of the let-7 small temporal RNA, Science 293 (2001) 834–8. Crossref, Google Scholar
40. K. Miyoshi, T. N. Okada, H. Siomi et al., Characterization of the miRNA-RISC loading complex and miRNA-RISC formed in the Drosophila miRNA pathway, RNA 15 (2009) 1282–91. Crossref, Google Scholar
41. A. Khvorova, A. Reynolds and S. D. Jayasena, Functional siRNAs and miRNAs exhibit strand bias, Cell 115 (2003) 209–16. Crossref, Google Scholar
42. K. Okamura, N. Liu and E. C. Lai, Distinct mechanisms for microRNA strand selection by Drosophila Argonautes, Mol. Cell 36 (2009) 431–44. Crossref, Google Scholar
43. S. Ro, C. Park, D. Young et al., Tissue-dependent paired expression of miRNAs, Nucleic Acids Res. 35 (2007) 5944–53. Crossref, Google Scholar
44. S. Bortoluzzi, M. Biasiolo and A. Bisognin, MicroRNA-offset RNAs (moRNAs): By-product spectators or functional players? Trends Mol Med 17 (2011) 473–4. Crossref, Google Scholar
45. D. P. Bartel, MicroRNAs: Target recognition and regulatory functions, Cell 136 (2009) 215–33. Crossref, Google Scholar
46. A. Eulalio, E. Huntzinger and E. Izaurralde, Getting to the root of miRNA-mediated gene silencing, Cell 132 (2008) 9–14. Crossref, Google Scholar
47. A. E. Pasquinelli, MicroRNAs and their targets: Recognition, regulation and an emerging reciprocal relationship, Nat. Rev. Genet. 13 (2012) 271–82. Crossref, Google Scholar
48. D. T. Humphreys, B. J. Westman, D. I. Martin et al., MicroRNAs control translation initiation by inhibiting eukaryotic initiation factor 4E/cap and poly(A) tail function, Proc. Natl. Acad. Sci. USA 102 (2005) 16961–6. Crossref, Google Scholar
49. M. P. Dragomir, E. Knutsen and G. A. Calin, SnapShot: Unconventional miRNA Functions, Cell 174 (2018b) 1038–1038e1. Crossref, Google Scholar
50. P. Guglielmelli, L. Tozzi, A. Pancrazzi et al., MicroRNA expression profile in granulocytes from primary myelofibrosis patients, Exp. Hematol. 35 (2007) 1708–18. Crossref, Google Scholar
51. K. Hussein, K. Theophile, W. Dralle et al., MicroRNA expression profiling of megakaryocytes in primary myelofibrosis and essential thrombocythemia, Platelets 20 (2009) 391–400. Crossref, Google Scholar
52. M. Girardot, C. Pecquet, S. Boukour et al., miR-28 is a thrombopoietin receptor targeting microRNA detected in a fraction of myeloproliferative neoplasm patient platelets, Blood 116 (2010) 437–45. Crossref, Google Scholar
53. K. D. Taganov, M. P. Boldin, K. J. Chang et al., NF-kappaB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses, Proc. Natl. Acad. Sci. USA 103 (2006) 12481–6. Crossref, Google Scholar
54. J. L. Zhao, D. S. Rao, M. P. Boldin et al., NF-kappaB dysregulation in microRNA-146a-deficient mice drives the development of myeloid malignancies, Proc. Natl. Acad. Sci. USA 108 (2011) 9184–9. Crossref, Google Scholar
55. F. Albano, L. Anelli, A. Zagaria et al., SETBP1 and miR_4319 dysregulation in primary myelofibrosis progression to acute myeloid leukemia, J. Hematol. Oncol. 5 (2012) 48. Crossref, Google Scholar
56. I. Cristobal, F. J. Blanco, L. Garcia-Orti et al., SETBP1 overexpression is a novel leukemogenic mechanism that predicts adverse outcome in elderly patients with acute myeloid leukemia, Blood 115 (2010) 615–25. Crossref, Google Scholar
57. I. Cristobal, L. Garcia-Orti, C. Cirauqui et al., PP2A impaired activity is a common event in acute myeloid leukemia and its activation by forskolin has a potent anti-leukemic effect, Leukemia 25 (2011) 606–14. Crossref, Google Scholar
58. R. R. Laborde, M. M. Patnaik, T. L. Lasho et al., SETBP1 mutations in 415 patients with primary myelofibrosis or chronic myelomonocytic leukemia: Independent prognostic impact in CMML, Leukemia 27 (2013) 2100–2. Crossref, Google Scholar
59. N. Gebauer, V. Bernard, W. Gebauer et al., MicroRNA expression and JAK2 allele burden in bone marrow trephine biopsies of polycythemia vera, essential thrombocythemia and early primary myelofibrosis, Acta Haematol. 129 (2013) 251–6. Crossref, Google Scholar
60. E. Tenedini, I. Bernardis, V. Artusi et al., Targeted cancer exome sequencing reveals recurrent mutations in myeloproliferative neoplasms, Leukemia 28 (2014) 1052–9. Crossref, Google Scholar
61. M. Xu, E. Bruno, J. Chao et al., The constitutive mobilization of bone marrow-repopulating cells into the peripheral blood in idiopathic myelofibrosis, Blood 105 (2005) 1699–705. Crossref, Google Scholar
62. R. Norfo, R. Zini, V. Pennucci et al., miRNA-mRNA integrative analysis in primary myelofibrosis CD34 $+$ cells: Role of miR-155/JARID2 axis in abnormal megakaryopoiesis, Blood 124 (2014) e21–32. Crossref, Google Scholar
63. K. Harada-Shirado, K. Ikeda, K. Ogawa et al., Dysregulation of the MIRLET7/HMGA2 axis with methylation of the CDKN2A promoter in myeloproliferative neoplasms, Br J. Haematol. 168 (2015) 338–49. Crossref, Google Scholar
64. M. Benati, M. Montagnana, E. Danese et al., Role of JAK2 V617F mutation and aberrant expression of microRNA-143 in myeloproliferative neoplasms, Clin. Chem. Lab. Med. 53 (2015) 1005–11. Crossref, Google Scholar
65. J. S. Ha and H. R. Jung, Up-regulation of microRNA 146b is associated with myelofibrosis in myeloproliferative neoplasms, Ann. Clin. Lab. Sci. 45 (2015) 308–14. Google Scholar
66. A. Tombak, O. I. Ay, M. E. Erdal et al., MicroRNA expression analysis in patients with primary myelofibrosis, polycythemia vera and essential thrombocythemia, Indian J. Hematol. Blood Transfus. 31 (2015) 416–25. Crossref, Google Scholar
67. P. Guglielmelli, A. Bisognin, C. Saccoman et al., Small RNA sequencing uncovers new miRNAs and moRNAs differentially expressed in normal and primary myelofibrosis CD34 $+$ Cells, PLOS ONE 10 (2015) e0140445. Crossref, Google Scholar
68. E. Bianchi, S. Ruberti, S. Rontauroli et al., Role of miR-34a-5p in hematopoietic progenitor cells proliferation and fate decision: Novel insights into the pathogenesis of primary myelofibrosis, Int. J. Mol. Sci. 18 (2017). Crossref, Google Scholar
69. S. Rontauroli, R. Norfo, V. Pennucci et al., miR-494-3p overexpression promotes megakaryocytopoiesis in primary myelofibrosis hematopoietic stem/progenitor cells by targeting SOCS6, Oncotarget 8 (2017) 21380–21397. Crossref, Google Scholar
70. N. Fan, Y. Tang, Z. Wu, M. Guan, B. Chen, X. Xu, W. Ma, X. Xu and X. Zhang, Elevated expression of the EZH2 gene in CALR-mutated patients with primary myelofibrosis, Ann. Hematol. 97 (2018) 1193–1208. Crossref, Google Scholar
71. C. Rossi, R. Zini, S. Rontauroli et al., Role of TGF-beta1/miR-382-5p/SOD2 axis in the induction of oxidative stress in CD34 $+$ cells from primary myelofibrosis, Mol. Oncol. 12 (2018) 2102–2123. Crossref, Google Scholar
72. E. Fuentes-Mattei, R. Bayraktar, T. Manshouri et al., miR-543 regulates the epigenetic landscape of myelofibrosis by targeting TET1 and TET2, JCI Insight 5 (2020). Crossref, Google Scholar
73. S. Volinia, M. Galasso, S. Costinean et al., Reprogramming of miRNA networks in cancer and leukemia, Genome Res 20 (2010) 589–99. Crossref, Google Scholar
74. A. L. Barabasi, and Z. N. Oltvai, Network biology: Understanding the cell’s functional organization, Nat. Rev. Genet. 5 (2004) 101–13. Crossref, Google Scholar
75. R. Spizzo, M. S. Nicoloso, C. M. Croce et al., SnapShot: MicroRNAs in Cancer, Cell 137 586–586e1. Crossref, Google Scholar
76. M. Dragomir, A. C. P. Mafra, S. M. G. Dias et al., Using microRNA Networks to Understand Cancer, Int. J. Mol. Sci. 19 (2018a). Crossref, Google Scholar
77. C. Vasilescu, M. Dragomir, M. Tanase et al., Circulating miRNAs in sepsis-A network under attack: An in-silico prediction of the potential existence of miRNA sponges in sepsis, PLOS ONE 12 (2017) e0183334. Crossref, Google Scholar
78. K. Van Roosbroeck, R. Bayraktar, S. Calin et al., The involvement of microRNA in the pathogenesis of Richter syndrome, Haematologica 104 (2019) 1004–1015. Crossref, Google Scholar
79. Y. Liu, B. Wei, X. Zhang et al., Identification of potential therapeutic target genes and miRNAs for primary myelofibrosis with microarray analysis, Exp. Ther. Med. 14 (2017) 2743–2750. Crossref, Google Scholar
80. E. Calura, S. Pizzini, A. Bisognin et al., A data-driven network model of primary myelofibrosis: Transcriptional and post-transcriptional alterations in CD34 $+$ cells, Blood Cancer J. 6 (2016) e439. Crossref, Google Scholar
81. J. Winter, MicroRNAs of the miR379-410 cluster: New players in embryonic neurogenesis and regulators of neuronal function, Neurogenesis (Austin) 2 (2015) e1004970. Crossref, Google Scholar
82. S. T. Da Rocha, C. A. Edwards, M. Ito et al., Genomic imprinting at the mammalian Dlk1-Dio3 domain, Trends Genet 24 (2008) 306–16. Crossref, Google Scholar
83. E. A. Glazov, S. Mcwilliam, W. C. Barris et al., Origin, evolution, and biological role of miRNA cluster in DLK-DIO3 genomic region in placental mammals, Mol Biol Evol 25 (2008) 939–48. Crossref, Google Scholar
84. V. Pennucci, R. Zini, R. Norfo et al., Abnormal expression patterns of WT1-as, MEG3 and ANRIL long non-coding RNAs in CD34 $+$ cells from patients with primary myelofibrosis and their clinical correlations, Leuk. Lymphoma 56 (2015) 492–6. Crossref, Google Scholar
85. P. Jelinic and P. Shaw, Loss of imprinting and cancer, J. Pathol. 211 (2007) 261–8. Crossref, Google Scholar
86. S. V. Laddha, S. Nayak, D. Paul et al., Genome-wide analysis reveals downregulation of miR-379/miR-656 cluster in human cancers, Biol. Direct 8 (2013) 10. Crossref, Google Scholar
87. S. Nayak, M. Aich, A. Kumar et al., Novel internal regulators and candidate miRNAs within miR-379/miR-656 miRNA cluster can alter cellular phenotype of human glioblastoma, Sci. Rep. 8 (2018) 7673. Crossref, Google Scholar
88. A. Kumar, S. Nayak, P. Pathak et al., Identification of miR-379/miR-656 (C14MC) cluster downregulation and associated epigenetic and transcription regulatory mechanism in oligodendrogliomas, J. Neurooncol. 139 (2018) 23–31. Crossref, Google Scholar
89. Y. Chen, L. Zhang and Q. Hao, Candidate microRNA biomarkers in human epithelial ovarian cancer: Systematic review profiling studies and experimental validation, Cancer Cell Int. 13 (2013) 86. Crossref, Google Scholar
90. S. Anfossi, A. Babayan, K. Pantel and G. A. Calin, Clinical utility of circulating non-coding RNAs — An update, Nat. Rev. Clin. Oncol. 15 (2018) 541–563. Crossref, Google Scholar
91. H. Valadi, K. Ekstrom, A. Bossios et al., Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells, Nat. Cell Biol. 9 (2007) 654–9. Crossref, Google Scholar
92. M. Mathieu, L. Martin-Jaular, G. Lavieu et al., Specificities of secretion and uptake of exosomes and other extracellular vesicles for cell-to-cell communication, Nat. Cell Biol. 21 (2019) 9–17. Crossref, Google Scholar
93. C. Villarroya-Beltri, F. Baixauli, C Gutierrez-Vazquez et al., Sorting it out: Regulation of exosome loading, Semin. Cancer Biol. 28 (2014) 3–13. Crossref, Google Scholar
94. R. Kalluri and V. S. Lebleu, The biology, function, and biomedical applications of exosomes, Science 367 (2020). Crossref, Google Scholar
95. E. Knutsen, T. Fiskaa, A. Ursvik et al., Performance comparison of digital microRNA profiling technologies applied on human breast cancer cell lines, PLOS ONE 8 (2013) e75813. Crossref, Google Scholar
96. M. P. Dragomir, S. Kopetz, J. A. Ajani and G. A. Calin, Non-coding RNAs in GI cancers: From cancer hallmarks to clinical utility, Gut 69 (2020) 748–763. Crossref, Google Scholar
97. M. Y. Shah, A. Ferrajoli, A. K. Sood et al., MicroRNA therapeutics in cancer — an emerging concept, EBioMedicine 12 (2016) 34–42. Crossref, Google Scholar
98. G. E. D. Petrescu, A. A. Sabo, L. I. Torsin et al., MicroRNA based theranostics for brain cancer: Basic principles, J. Exp. Clin. Cancer Res. 38 (2019) 231. Crossref, Google Scholar
99. H. Ling, M. Fabbri and G. A. Calin, MicroRNAs and other non-coding RNAs as targets for anticancer drug development, Nat. Rev. Drug. Discov. 12 (2013) 847–65. Crossref, Google Scholar
100. K. Van Roosbroeck, F. Fanini, T. Setoyama et al., Combining anti-mir-155 with chemotherapy for the treatment of lung cancers, Clin. Cancer Res. 23 (2017) 2891–2904. Crossref, Google Scholar
101. A. Tefferi, T. L. Lasho, C. M. Finke et al., CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: Clinical, cytogenetic and molecular comparisons, Leukemia 28 (2014b) 1472–7. Crossref, Google Scholar
102. T. Barbui, A. Tefferi, A. M. Vannucchi et al., Philadelphia chromosome-negative classical myeloproliferative neoplasms: Revised management recommendations from European LeukemiaNet, Leukemia 32 (2018) 1057–1069. Crossref, Google Scholar
103. D. A. C. Fisher, C. A. Miner, E. K. Engle et al., Cytokine production in myelofibrosis exhibits differential responsiveness to JAK-STAT, MAP kinase, and NFkappaB signaling, Leukemia 33 (2019) 1978–1995. Crossref, Google Scholar